GKIM
ITCI

GW&K Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

GW&K Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-141,109
Closed -$18.6M – 1050
2025
Q1 		$18.6M Sell
141,109
-1,246,353
-90% -$155M 0.17% 207
2024
Q4 		$116M Sell
1,387,462
-6,734
-0.5% -$553K 0.99% 7
2024
Q3 		$102M Buy
1,394,196
+218
+0% +$16.4K 0.87% 12
2024
Q2 		$95.5M Sell
1,393,978
-204,986
-13% -$14.2M 0.87% 13
2024
Q1 		$111M Sell
1,598,964
-29,280
-2% -$2.01M 0.98% 9
2023
Q4 		$117M Sell
1,628,244
-63,836
-4% -$3.67M 1.09% 6
2023
Q3 		$88.1M Sell
1,692,080
-35,207
-2% -$2.05M 0.89% 11
2023
Q2 		$109M Sell
1,727,287
-25,780
-1% -$1.61M 1.04% 7
2023
Q1 		$94.9M Buy
1,753,067
+302,685
+21% +$14.6M 0.92% 11
2022
Q4 		$76.8M Sell
1,450,382
-15,453
-1% -$774K 0.78% 19
2022
Q3 		$68.2M Buy
1,465,835
+882,242
+151% +$46.1M 0.75% 23
2022
Q2 		$33.3M Buy
583,593
+34,266
+6% +$1.94M 0.36% 127
2022
Q1 		$33.6M Buy
549,327
+176,007
+47% +$9.14M 0.3% 151
2021
Q4 		$19.5M Buy
+373,320
New +$15.7M 0.16% 197

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GW&K Investment Management's ITCI Position: Q2 2025 in Review

GW&K Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 141,109 shares — an estimated $18.6M sold.

GW&K Investment Management first reported a position in ITCI in Q4 2021 and held it in 14 quarters. The position peaked at $117M in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • GW&K Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • GW&K Investment Management sold 141,109 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $18.6M.
  • GW&K Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 14 quarters.
  • GW&K Investment Management's Intra-Cellular Therapies Inc. position peaked at $117M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on GW&K Investment Management's 13F filing for Q2 2025, filed 11 Aug 2025.